Cargando…

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy

BACKGROUND: Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV) infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic hepatitis C (CHC), and the effect of pegylated interferon alfa-2b plus ribavirin combination therapy on oxidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Levent, Görenek, Ali, Acar, Ahmet, Aydın, Polat, Eyigun Can, Aytaç, Çetinkaya, Ayşe, Eken, Ahmet, Sayal
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513604/
https://www.ncbi.nlm.nih.gov/pubmed/16787540
http://dx.doi.org/10.1186/1479-5876-4-25
_version_ 1782128513572143104
author Levent, Görenek
Ali, Acar
Ahmet, Aydın
Polat, Eyigun Can
Aytaç, Çetinkaya
Ayşe, Eken
Ahmet, Sayal
author_facet Levent, Görenek
Ali, Acar
Ahmet, Aydın
Polat, Eyigun Can
Aytaç, Çetinkaya
Ayşe, Eken
Ahmet, Sayal
author_sort Levent, Görenek
collection PubMed
description BACKGROUND: Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV) infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic hepatitis C (CHC), and the effect of pegylated interferon alfa-2b plus ribavirin combination therapy on oxidative stress. METHODS: Nineteen patients with chronic HCV infection and 28 healthy controls were included in the study. In control and patient groups, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, erythrocyte malondialdehyde (MDA) levels, erythrocyte CuZn-superoxide dismutase (SOD), erythrocyte glutathione peroxidase (GSH-Px) activities were measured. After pegylated interferon alfa-2b and ribavirin combination therapy for 48 weeks, these parameters were measured again in the patient group. RESULTS: Serum MDA levels increased significantly in CHC patients (n:19), before the treatment when compared with healthy subjects (n:28) 9.28 ± 1.61, 4.20 ± 1.47 nmol/ml, p < 0.001 respectively. MDA concentration decreased significantly (p < 0.001) after the treatment as well as ALT, AST activity, in erythrocytes of these patients. Average antioxidant enzymes (superoxide dismutase and glutathione peroxidase) were significantly lower in erythrocytes of patients with CHC before treatment compared with the control group (both, p < 0.001). Chronic Hepatitis C patients after pegylated interferon alfa-2b and ribavirin therapy showed values of SOD, GSH-Px were significantly higher than pretreatment levels (both, p < 0.001). CONCLUSION: Our results show that patients with chronic HCV infection are under the influence of oxidative stress associated with lower levels of antioxidant enzymes. These impairments return to level of healthy controls after pegylated interferon alfa-2b plus ribavirin combination therapy of CHC patients. Although interferon and ribavirin are not antioxidants, their antiviral capacity might reduce viral load, and inflammation, and perhaps through this mechanism might reduce virus-induced oxidative stress.
format Text
id pubmed-1513604
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15136042006-07-22 Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy Levent, Görenek Ali, Acar Ahmet, Aydın Polat, Eyigun Can Aytaç, Çetinkaya Ayşe, Eken Ahmet, Sayal J Transl Med Research BACKGROUND: Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV) infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic hepatitis C (CHC), and the effect of pegylated interferon alfa-2b plus ribavirin combination therapy on oxidative stress. METHODS: Nineteen patients with chronic HCV infection and 28 healthy controls were included in the study. In control and patient groups, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, erythrocyte malondialdehyde (MDA) levels, erythrocyte CuZn-superoxide dismutase (SOD), erythrocyte glutathione peroxidase (GSH-Px) activities were measured. After pegylated interferon alfa-2b and ribavirin combination therapy for 48 weeks, these parameters were measured again in the patient group. RESULTS: Serum MDA levels increased significantly in CHC patients (n:19), before the treatment when compared with healthy subjects (n:28) 9.28 ± 1.61, 4.20 ± 1.47 nmol/ml, p < 0.001 respectively. MDA concentration decreased significantly (p < 0.001) after the treatment as well as ALT, AST activity, in erythrocytes of these patients. Average antioxidant enzymes (superoxide dismutase and glutathione peroxidase) were significantly lower in erythrocytes of patients with CHC before treatment compared with the control group (both, p < 0.001). Chronic Hepatitis C patients after pegylated interferon alfa-2b and ribavirin therapy showed values of SOD, GSH-Px were significantly higher than pretreatment levels (both, p < 0.001). CONCLUSION: Our results show that patients with chronic HCV infection are under the influence of oxidative stress associated with lower levels of antioxidant enzymes. These impairments return to level of healthy controls after pegylated interferon alfa-2b plus ribavirin combination therapy of CHC patients. Although interferon and ribavirin are not antioxidants, their antiviral capacity might reduce viral load, and inflammation, and perhaps through this mechanism might reduce virus-induced oxidative stress. BioMed Central 2006-06-20 /pmc/articles/PMC1513604/ /pubmed/16787540 http://dx.doi.org/10.1186/1479-5876-4-25 Text en Copyright © 2006 Levent et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Levent, Görenek
Ali, Acar
Ahmet, Aydın
Polat, Eyigun Can
Aytaç, Çetinkaya
Ayşe, Eken
Ahmet, Sayal
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
title Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
title_full Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
title_fullStr Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
title_full_unstemmed Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
title_short Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
title_sort oxidative stress and antioxidant defense in patients with chronic hepatitis c patients before and after pegylated interferon alfa-2b plus ribavirin therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513604/
https://www.ncbi.nlm.nih.gov/pubmed/16787540
http://dx.doi.org/10.1186/1479-5876-4-25
work_keys_str_mv AT leventgorenek oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy
AT aliacar oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy
AT ahmetaydın oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy
AT polateyiguncan oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy
AT aytaccetinkaya oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy
AT ayseeken oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy
AT ahmetsayal oxidativestressandantioxidantdefenseinpatientswithchronichepatitiscpatientsbeforeandafterpegylatedinterferonalfa2bplusribavirintherapy